Clinical Trial

Patient-reported Outcomes (PRO) and Treatment Outcomes of Chinese Patients With MSS-type Advanced Colorectal Cancer Who Received the Zidovudine Combination Regimen in the Real World

Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated August 6, 2025 (before its estimated July 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The Chidamide + sintilimab ± bevacizumab regimen has become a post-treatment option for clinicians and patients after being included in the guidelines. The CAPability-01 study is a phase II RCT, with a limited number of enrolled subjects. Further observation of the safety and clinical real-world application status of the sidibemab combination regimen is needed in a larger sample size prospective observational cohort study. The primary endpoint of this study is the safety events of the sidibemab combination regimen.
Trial Details
NCT Number NCT07105631
Lead Sponsor West China Hospital
Conditions Colorectal Cancer
Enrollment 300 participants
Start Date 2025-07-10
Primary Completion 2026-07-30 (estimated)
Study Completion 2027-07-30 (estimated)
Updated on ClinicalTrials.gov 2025-08-06